Stockscreener 앱 받기
71.61
4.49%
3.08
시간 외 거래:
71.00
-0.61
-0.85%
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
Market Catalysts: Whats next for BridgeBio Pharma Inc stock2026 Technical Overview & Fast Gaining Stock Reports - baoquankhu1.vn
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions - The Manila Times
BridgeBio heart drug lands late-breaking ACC slot with survival data - Stock Titan
Aug Retail: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARPortfolio Profit Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
BridgeBio Pharma, Inc. (BBIO) Latest Stock News & Headlines - Yahoo Finance
BridgeBio Pharma (BBIO) President and CFO receives 59,041 RSU equity grant - Stock Titan
BridgeBio (BBIO) CAO awarded 14,170 RSUs in new equity grant - Stock Titan
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio gives 29 new hires stock awards totaling 70,916 shares - Stock Titan
BridgeBio (BBIO) CEO Neil Kumar awarded options and 104,313 RSUs - Stock Titan
Mizuho Raises Price Target on BridgeBio Pharma to $106 From $91, Keeps Outperform Rating - marketscreener.com
BridgeBio Pharma launches initiative to define age-specific pathways for FGFR3 testing - Traders Union
Mizuho raises BridgeBio Pharma stock price target on drug strength By Investing.com - Investing.com Canada
Mizuho raises BridgeBio Pharma stock price target on drug strength - Investing.com
Mizuho Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
BBIO: Mizuho Raises Price Target to $106, Maintains 'Outperform' Rating | BBIO Stock News - GuruFocus
Raymond James Maintains BridgeBio Pharma (BBIO) Outperform Recommendation - MSN
BridgeBio outlines transition to cash generation by 2028 with $600M profit target, driven by pipeline advances and Attruby growth - MSN
BridgeBio Pharma Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Aug Sectors: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARMarket Performance Summary & Entry Point Strategy Guides - baoquankhu1.vn
Resistance Check: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEAR2026 Trade Ideas & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
BBIO PE Ratio & Valuation, Is BBIO Overvalued - Intellectia AI
(BBIO) Risk Channels and Responsive Allocation - Stock Traders Daily
Fred Alger Management LLC Has $10.25 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma CEO Kumar Neil sells $5.5m in BBIO stock - Investing.com Nigeria
BridgeBio Pharma CEO Kumar Neil sells $5.5m in BBIO stock By Investing.com - Investing.com South Africa
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat
BridgeBio (BBIO) CEO’s family trusts sell 80,000 company shares - Stock Titan
HighVista Strategies LLC Raises Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Granahan Investment Management LLC Buys 78,588 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Farallon Capital Management LLC Has $425.49 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback - Yahoo Finance
The week in pharma: action, reaction and insight – week to March 13, 2026 - The Pharma Letter
Boone Capital Management LLC Buys Shares of 460,282 BridgeBio Pharma, Inc. $BBIO - MarketBeat
Prosight Management LP Sells 208,187 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BBIO6336503 Bond Risk Analysis - TradingView
BBIO6336503 Bond Coupon Analysis — Rate & Payments - TradingView
How Positive Phase 3 LGMD Data Could Shape BridgeBio Pharma’s (BBIO) Risk Profile and Upside Potential - simplywall.st
BBIO (NASDAQ: BBIO) — Trustee and Insider 10b5-1 Sales Listed - Stock Titan
Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Tenet Healthcare (THC) - The Globe and Mail
BridgeBio Touts Attruby Uptake, Bayer's Europe Rollout, and Pipeline Timelines - National Today
BridgeBio Pharma Touts Attruby Uptake, Bayer’s Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf - MarketBeat
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - MarketBeat
BridgeBio Looks At Genetic Testing To Build Out BBP-418 Launch In LGMD2I/R9 - Citeline News & Insights
BridgeBio Pharma Director Sells Shares - TradingView
BridgeBio director sells 8,671 shares after option exercise | BBIO SEC FilingForm 4 - Stock Titan
BridgeBio (BBIO) soars 13% on double-digit price target upgrade - MSN
A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - simplywall.st
BridgeBio reports Phase III progress for BBP-418 - The Pharma Letter
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga
Barclays Maintains Overweight on BridgeBio Pharma (BBIO) March 2026 - Meyka
Capital Research Global Investors Sells 2,055,172 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio (BBIO) Reports Promising Phase 3 Data for BBP-418 in M - GuruFocus
BridgeBio Pharma Presents Promising Phase 3 FORTIFY Interim Analysis Results for BBP-418 in LGMD2I/R9 at MDA Conference - Quiver Quantitative
BridgeBio Pharma plans to submit NDA for BBP-418 to FDA in H1 2026 - marketscreener.com
Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026 - TradingView
LGMD trial drug lets people finish 100m test 31s faster than placebo - Stock Titan
BridgeBio (BBIO) Reports Wider Q4 Loss of $1/Share vs $0.63 Estimate; Stock Surges 13% - AlphaStreet
HC Wainwright Raises Earnings Estimates for BridgeBio Pharma - MarketBeat
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 - Yahoo Finance
BridgeBio (BBIO) Sees Price Target Boost and Earns Overweight Ra - GuruFocus
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade - Insider Monkey
1.82%
자본화:
|
볼륨(24시간):